MOC Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Molecure S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł14.92 |
| 52 Week High | zł25.50 |
| 52 Week Low | zł14.14 |
| Beta | 2.2 |
| 1 Month Change | 2.75% |
| 3 Month Change | -16.65% |
| 1 Year Change | -32.18% |
| 3 Year Change | -68.59% |
| 5 Year Change | 2.19% |
| Change since IPO | -48.55% |
Recent News & Updates
Recent updates
Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Apr 20
We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate
Dec 01Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?
Jul 07Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Mar 10Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth
Aug 16OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem
Nov 04Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?
Feb 24Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?
Jan 02Shareholder Returns
| MOC | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | -5.0% | -1.8% | -1.7% |
| 1Y | -32.2% | -9.3% | 21.5% |
Return vs Industry: MOC underperformed the Polish Pharmaceuticals industry which returned -9.3% over the past year.
Return vs Market: MOC underperformed the Polish Market which returned 21.5% over the past year.
Price Volatility
| MOC volatility | |
|---|---|
| MOC Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PL Market | 9.2% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: MOC's share price has been volatile over the past 3 months.
Volatility Over Time: MOC's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 109 | Marcin Szumowski | molecure.com |
Molecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program.
Molecure S.A. Fundamentals Summary
| MOC fundamental statistics | |
|---|---|
| Market cap | zł251.19m |
| Earnings (TTM) | -zł29.46m |
| Revenue (TTM) | zł1.95m |
128.7x
P/S Ratio-8.5x
P/E RatioIs MOC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOC income statement (TTM) | |
|---|---|
| Revenue | zł1.95m |
| Cost of Revenue | zł3.69m |
| Gross Profit | -zł1.74m |
| Other Expenses | zł27.71m |
| Earnings | -zł29.46m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 27, 2024
| Earnings per share (EPS) | -1.75 |
| Gross Margin | -89.31% |
| Net Profit Margin | -1,509.30% |
| Debt/Equity Ratio | 0% |
How did MOC perform over the long term?
See historical performance and comparison